Has the blood of Uyghur’s been forcibly harvested to fill China’s dwindling domestic stocks?

CHINA is plundering the Uyghur minority for their blood by conducting wide-scale forced withdrawals amid Beijing’s anxieties over diminishing voluntary donations throughout the rest of the country, a recent study alleges.

The study has revealed how Beijing authorities conducting a DNA sample of 23 million Uyghur in Xinjiang in the name of “health check-ups”.

Following the sampling project the report concludes that the Uyghur ethnicity are being subjected to repeated forced blood withdrawals.

This has led to an increase in the amount of blood donations within China as a whole.

Chinese voluntary blood donations

Due to traditional Chinese values, the voluntary blood donation rate in China has always been relatively low and it is described as an increase of 4.2% and 5.0% respectively compared to 2016”. 

The study alleges this increase in blood donation rates is due to forced withdrawals within Xinjiang, which it claims has become “an open air prison with almost all Uyghurs being monitored by the Chinese government, making it very difficult to determine whether the blood donors donate blood voluntarily.”

• MEXC: An Emerging Powerhouse in the Cryptocurrency Exchange Landscape
• SafePal S1 Pro: The Game-Changing Crypto Hardware Wallet
• 2024 US Election: Bitcoin’s rise as a policy decision tied to shift in young voter priorities
• US banks model CBDC transactions on shared ledger

Discrepancies in Xinjiang

The report states that, “the blood donation rate in Xinjiang is much higher than any parts of China resulting in a tremendous amount of plasma collected from the local Uyghur people; it is very difficult to rule out the possibility of forced blood donations.”

The report names a blood products company operating within Xinjiang as ranking “among the top in the domestic blood products industry”.

The report maintains that Xinjiang based blood products company is collecting significantly more blood per head of population than any other blood products company in China. It said: “They have expand their production capacity for blood products based on the existing annual treatment capability of 800-1000 tons of plasma.

It said: “This is equivalent to about 10% to 12.5% of the total plasma collected from entire China.
 
“This ratio is extremely large for Xinjiang, which accounts for only 1.7% of the total population of China.”

Vulnerability of Uighur community

The report suggests that the Uyghur ethnicity in Xinjiang province are in a very vulnerable position.

It describes them being in significant threat of exploitation by biotech companies who see a vulnerable resource that they can plunder for quick profits.

It said: “The blood products are becoming the most important source of income and profit for listed biotech companies in China.

“It is most likely that Uyghurs as a vulnerable group could become the victims of Chinese blood products market.”

Chinese blood products market

In 2015 China Biologic Products, Inc, a major Chinese based biopharmaceutical company stated that its subsidary, Guizhou Taibang Biological Products Co., Ltd, has commenced a collaboration with the Xinjiang Deyuan blood products company.

The collaboration will allow China Biologic Products to source raw plasma from the Xinjiang based blood products company, to the order of 500 tonnes of source plasma over a three year period.

When contacted, the Xinjiang Deyuan Biological Engineering Co., Ltd. have yet to respond to the details of the report